keyword
MENU ▼
Read by QxMD icon Read
search

Cataract dme

keyword
https://www.readbyqxmd.com/read/27926909/dexamethasone-implant-in-chronic-diabetic-macular-edema-resistant-to-intravitreal-ranibizumab-treatment
#1
Ozlem Eski Yucel, Ertugrul Can, Hilal Eser Ozturk, Hakki Birinci, Yuksel Sullu
PURPOSE: The aim of this study was to assess the efficacy of a single intravitreal dexamethasone implant (IDI) over 6 months in eyes with chronic diabetic macular edema (DME) that were resistant to intravitreal ranibizumab (IR) treatment. METHODS: This retrospective study was conducted at the Ondokuz Mayis University Hospital, Samsun, Turkey. Efficacy outcomes were considered as the change from baseline in best corrected visual acuity (BCVA) and central macular thickness (CMT)...
December 8, 2016: Ophthalmic Research
https://www.readbyqxmd.com/read/27754737/comparative-effects-of-topical-diclofenac-and-betamethasone-on-inflammation-after-vitrectomy-and-cataract-surgery-in-various-vitreoretinal-diseases
#2
Kanako Yasuda, Ryosuke Motohashi, Osamu Kotake, Hayate Nakagawa, Hidetaka Noma, Masahiko Shimura
PURPOSE: To compare the effects of topical diclofenac and betamethasone on postoperative inflammation after combined sutureless cataract and vitreoretinal surgery in patients with macular hole (MH), epiretinal membrane (ERM), diabetic macular edema (DME), and rhegmatogenous retinal detachment (RRD). METHODS: The study involved 180 eligible eyes that underwent the combined surgery, followed by treatment with topical diclofenac (n = 100) or betamethasone (n = 80) for 12 weeks...
December 2016: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27661663/management-of-macular-oedema-in-diabetic-patients-undergoing-cataract-surgery
#3
Francesco Boscia, Ermete Giancipoli, Giuseppe D'Amico Ricci, Antonio Pinna
PURPOSE OF REVIEW: The aim of this study was to describe all the treatment modalities used to prevent and manage macular oedema in diabetic patients undergoing cataract surgery. RECENT FINDINGS: Topical NSAIDs have been proposed to be an effective strategy to prevent postsurgical macular oedema (PME) in diabetic patients. The prophylactic use of intravitreal antivascular endothelial growth factors (anti-VEGF) drugs and steroids in these patients, even if effective, brings some concerns with regard to possible side effects...
January 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/27660409/update-on-corticosteroids-for-diabetic-macular-edema
#4
REVIEW
Stephen G Schwartz, Ingrid U Scott, Michael W Stewart, Harry W Flynn
Diabetic macular edema (DME) remains an important cause of visual loss. Although anti-vascular endothelial growth factor (VEGF) agents are generally used as first-line treatments for patients with center-involving DME, there is an important role for corticosteroids as well. Corticosteroids may be especially useful in pseudophakic patients poorly responsive to anti-VEGF therapies, in patients wishing to reduce the number of required injections, and in pregnant patients. Intravitreal triamcinolone acetonide has been used for many years but is not approved for this indication...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27651226/intravitreal-aflibercept-for-diabetic-macular-edema-148-week-results-from-the-vista-and-vivid-studies
#5
Jeffrey S Heier, Jean-François Korobelnik, David M Brown, Ursula Schmidt-Erfurth, Diana V Do, Edoardo Midena, David S Boyer, Hiroko Terasaki, Peter K Kaiser, Dennis M Marcus, Quan D Nguyen, Glenn J Jaffe, Jason S Slakter, Christian Simader, Yuhwen Soo, Thomas Schmelter, Robert Vitti, Alyson J Berliner, Oliver Zeitz, Carola Metzig, Frank G Holz
PURPOSE: To compare efficacy and safety of intravitreal aflibercept injection (IAI) with macular laser photocoagulation for diabetic macular edema (DME) over 3 years. DESIGN: Two similarly designed phase 3 trials: VISTA(DME) and VIVID(DME). PARTICIPANTS: Patients (eyes; n = 872) with central-involved DME. METHODS: Eyes received IAI 2 mg every 4 weeks (2q4), IAI 2 mg every 8 weeks after 5 monthly doses (2q8), or laser control...
November 2016: Ophthalmology
https://www.readbyqxmd.com/read/27632215/a-multicenter-12-month-randomized-study-comparing-dexamethasone-intravitreal-implant-with-ranibizumab-in-patients-with-diabetic-macular-edema
#6
David G Callanan, Anat Loewenstein, Sunil S Patel, Pascale Massin, Borja Corcóstegui, Xiao-Yan Li, Jenny Jiao, Yehia Hashad, Scott M Whitcup
PURPOSE: To evaluate whether treatment with dexamethasone intravitreal implant (DEX implant) 0.7 mg every 5 months provides a similar average change in best-corrected visual acuity (BCVA) from baseline as ranibizumab 0.5 mg administered as per its European Summary of Product Characteristics in patients with diabetic macular edema (DME). METHODS: This was a multicenter, open-label, 12-month, randomized, parallel-group, noninferiority study in patients with DME (one eye/patient)...
September 8, 2016: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/27493795/comparison-of-perioperative-ranibizumab-injections-for-diabetic-macular-edema-in-patients-undergoing-cataract-surgery
#7
Erhan Yumuşak, Kemal Örnek
Purpose. To compare the efficacy of perioperative ranibizumab injections on diabetic macular edema (DME) in patients undergoing cataract surgery. Methods. This study included 59 eyes of 59 patients. All patients had advanced cataract with DME and underwent an uneventful phacoemulsification surgery. There were 3 subgroups. The first group received intravitreal ranibizumab injection 2 weeks preoperatively, the second group received intraoperatively, and the third group received 2 weeks postoperatively. Follow-up examinations were performed at 1 week as well as at 1 and 3 months...
2016: Journal of Ophthalmology
https://www.readbyqxmd.com/read/27467659/matrix-metalloproteinase-1-and-matrix-metalloproteinase-9-in-the-aqueous-humor-of-diabetic-macular-edema-patients
#8
Jin-Woo Kwon, Jin A Choi, Donghyun Jee
PURPOSE: To assess the concentrations of matrix metalloproteinase (MMP)-1 and MMP-9 in the aqueous humor of diabetic macular edema (DME) patients. METHOD: The concentrations of MMP-1 and MMP-9 in the aqueous humors of 15 cataract patients and 25 DME patients were compared. DME patients were analyzed according to the diabetic retinopathy (DR) stage, diabetes mellitus (DM) duration, pan-retinal photocoagulation (PRP) treatment, recurrence within 3 months, HbA1C (glycated hemoglobin) level, and axial length...
2016: PloS One
https://www.readbyqxmd.com/read/27273720/safety-and-feasibility-of-quantitative-multiplexed-cytokine-analysis-from-office-based-vitreous-aspiration
#9
Devon H Ghodasra, Ryan Fante, Thomas W Gardner, Michael Langue, Leslie M Niziol, Cagri Besirli, Steven R Cohen, Vaidehi S Dedania, Hakan Demirci, Nieraj Jain, K Thiran Jayasundera, Mark W Johnson, Partho S Kalyani, Rajesh C Rao, David N Zacks, Jeffrey M Sundstrom
PURPOSE: The goals of this study were to evaluate the safety of office-based vitreous sampling, and determine the utility of these samples with multiplex cytokine analysis. METHODS: Vitreous samples were collected from office-based needle aspiration and the rate of adverse events during follow-up was reviewed. The vitreous cytokine concentrations in a subset of patients with diabetic macular edema (DME) were analyzed using a 42 plex-cytokine bead array. These results were compared with vitreous cytokine concentrations in proliferative diabetic retinopathy (PDR) and controls (macular hole, epiretinal membrane, symptomatic vitreous floaters) from pars plana vitrectomy...
June 1, 2016: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/27273597/association-of-plasma-semaphorin-3a-with-phenotypes-of-diabetic-retinopathy-and-nephropathy
#10
Soo Hyun Kwon, Jae Pil Shin, In Taek Kim, Dong Ho Park
PURPOSE: To investigate whether diabetic retinopathy phenotypes and albuminuria are associated with the overexpression of plasma semaphorin 3A (Sema3A). METHODS: The study group with severe nonproliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR), the diabetes without diabetic retinopathy group, and the control group without diabetes consisted of all consecutive patients who were scheduled to undergo intravitreal bevacizumab injection for treatment-naïve diabetic macular edema (DME) and senile cataract surgery, respectively...
June 1, 2016: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/27215008/an-updated-review-of-long-term-outcomes-from-randomized-controlled-trials-in-approved-pharmaceuticals-for-diabetic-macular-edema
#11
REVIEW
Jia-Kang Wang, Tzu-Lun Huang, Pei-Yuan Su, Pei-Yao Chang
Diabetic macular edema (DME) is a major sight-threatening cause in diabetic patients. We review the long-term outcome of four approved pharmacotherapy for treating DME, including intravitreal injections of corticosteroids (dexamethasone implants and fluocinolone acetonide inserts) and anti-vascular endothelial growth factor (VEGF) (ranibizumab and aflibercept). They all show superior ability to improve vision and reduce macular thickness, comparing with sham injections or macular focal/grid laser treatment...
December 2015: Eye Science
https://www.readbyqxmd.com/read/27190127/three-month-outcome-of-intravitreal-ziv-aflibercept-in-eyes-with-diabetic-macular-oedema
#12
Ahmad M Mansour, Chintan Dedhia, Jay Chhablani
PURPOSE: We report the 3-month efficacy of monthly intravitreal ziv-aflibercept in patients with diabetic macular oedema (DME). METHODS: Prospectively, consecutive patients with DME underwent intravitreal injection of 0.05 ml of compounded ziv-aflibercept (1.25 mg) from March 2015 to November 2015. Monitoring of best-corrected visual acuity (BCVA), intraocular inflammation, cataract progression and retinal structure by spectral domain optical coherence tomography was carried out at baseline, 1 week, 1 month, 2 months and 3 months after 3 monthly injections...
May 17, 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27096289/forming-a-consensus-data-and-guidance-for-physicians-treating-diabetic-macular-edema
#13
Carmen A Puliafito, Scott W Cousins, Jason Bacharach, Victor H Gonzalez, Nancy M Holekamp, Pauline T Merrill, Matthew P Ohr, Richard K Parrish, Christopher D Riemann
The diabetic macular edema (DME) treatment paradigm has evolved as the understanding of the disease pathology has grown. Since 2012, four pharmacotherapies have been approved by the U.S. Food and Drug Administration for the treatment of DME. First-line treatment of DME with anti-vascular endothelial growth factor [VEGF] agents has become the gold standard; however, an appreciable percentage of patients do not respond to anti-VEGF therapies. In patients who inadequately respond to anti-VEGF therapies, the underlying disease pathology may be mediated by a multitude of growth factors and inflammatory cytokines...
April 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27079207/long-term-efficacy-and-safety-of-intravitreal-dexamethasone-implant-for-the-treatment-of-diabetic-macular-edema
#14
Frederic Matonti, Stephan Pommier, Franck Meyer, Christian Hajjar, Pierre Yves Merite, Eric Parrat, Herve Rouhette, Olivier Rebollo, Sebastien Guigou
PURPOSE: To evaluate the long-term efficacy and safety of the dexamethasone intravitreal implant Ozurdex® in the treatment of diabetic macular edema (DME). METHODS: This was a retrospective noncomparative study. A total of 23 patients with DME followed for at least 12 months were included. All patients were treated with at least 2 Ozurdex® injections for the treatment of DME. Best-corrected visual acuity, central retinal thickness, intraocular pressure (IOP), and cataract progression were recorded over 12 months...
August 4, 2016: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/27041989/treatment-costs-of-cystoid-macular-edema-among-patients-following-cataract-surgery
#15
Jordana K Schmier, David W Covert, Carolyn K Hulme-Lowe, Anmol Mullins, Emmanuel M Mahlis
PURPOSE: The current costs of treating cystoid macular edema (CME), a complication that can follow cataract surgery, are largely unknown. This analysis estimates the treatment costs for CME based on the recently released US Medicare data. SETTING: Nationally representative database. DESIGN: Retrospective analysis of the 2011 through 2013 Medicare 5% Beneficiary Encrypted Files. METHODS: Beneficiaries who underwent cataract surgery were identified and stratified by diagnosis of CME (cases) or no diagnosis of CME (controls) within 6 months following surgery...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/26949615/macular-edema-after-cataract-surgery-in-diabetic-eyes-evaluated-by-optical-coherence-tomography
#16
Xiao-Yong Chen, Wen-Jun Song, Hong-Yuan Cai, Lin Zhao
AIM: To assess quantitative changes of the macula in diabetic eyes after cataract surgery using optical coherence tomography (OCT) and to estimate the incidence of development or worsening of macular edema (ME) in diabetic eyes with or without pre-existing ME. METHODS: In this prospective, observational study, 92 eyes of 60 diabetic patients who underwent cataract surgery were evaluated before surgery and 1, 3mo after surgery using OCT. Macular thickness was measured with OCT at nine macular subfields defined by the 9 zones early treatment of diabetic retinopathy study (ETDRS), as well as total macular volume obtained by OCT at 1, 3mo after surgery were compared with baseline features obtained before surgery...
2016: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/26871700/diabetic-macular-edema-at-the-time-of-cataract-surgery-trial-a-prospective-randomized-clinical-trial-of-intravitreous-bevacizumab-versus-triamcinolone-in-patients-with-diabetic-macular-oedema-at-the-time-of-cataract-surgery-preliminary-6-month-results
#17
Lyndell L Lim, Julie L Morrison, Marios Constantinou, Sophie Rogers, Sukhpal S Sandhu, Sanjeewa S Wickremasinghe, Ryo Kawasaki, Salmaan Al-Qureshi
BACKGROUND: To compare visual and anatomical outcomes between intravitreous bevacizumab (BVB, Avastin) and triamcinolone (TA, Triesence) when administered at the time of cataract surgery in patients with diabetic macular oedema (DME). DESIGN: Prospective, single-masked, randomized clinical trial at The Royal Victorian Eye and Ear Hospital, Melbourne. PARTICIPANTS: Patients with clinically significant cataract and either centre-involving DME or DME treated within the previous 24 months...
May 2016: Clinical & Experimental Ophthalmology
https://www.readbyqxmd.com/read/26681198/fluocinolone-acetonide-for-the-treatment-of-diabetic-macular-edema
#18
Christos Haritoglou, Wolfgang Mayer, Armin Wolf
In addition to VEGF inhibitors such as ranibizumab, aflibercept or bevacizumab, clinical and experimental investigations have revealed the great potential of steroids in the treatment of DME. At present two intravitreal steroid inserts are approved for the treatment of DME containing either dexamethasone or fluocinolone acetat (FA) as a pharmacological compound. The non degradable intravitreal FA insert releases 0.2 µg FA per day (Iluvien, Alimera Sciences). Clinical phase III studies have demonstrated the beneficial effect of the FA insert to last up to three years, especially in patients with a prolonged history of DME of at least three years at the initiation of therapy...
2016: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/26567783/differentiation-of-diabetic-macular-edema-from-pseudophakic-cystoid-macular-edema-by-spectral-domain-optical-coherence-tomography
#19
Marion R Munk, Lee M Jampol, Christian Simader, Wolfgang Huf, Tamara J Mittermüller, Glenn J Jaffe, Ursula Schmidt-Erfurth
PURPOSE: To differentiate diabetic macular edema (DME) from pseudophakic cystoid macular edema (PCME) based solely on spectral-domain optical coherence tomography (SD-OCT). METHODS: This cross-sectional study included 134 participants: 49 with PCME, 60 with DME, and 25 with diabetic retinopathy (DR) and ME after cataract surgery. First, two unmasked experts classified the 25 DR patients after cataract surgery as either DME, PCME, or mixed-pattern based on SD-OCT and color-fundus photography...
October 2015: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/26457195/risk-factors-for-refractory-diabetic-macular-oedema-after-sub-tenon-s-capsule-triamcinolone-acetonide-injection
#20
Toshiyuki Oshitari, Yuta Kitamura, Sakiko Nonomura, Miyuki Arai, Yoko Takatsuna, Eiju Sato, Takayuki Baba, Shuichi Yamamoto
The purpose of this study is to identify the risk factors for a recurrence or persistence of diabetic macular oedema (DME) after a sub-Tenon's capsule triamcinolone acetonide (STTA) injection. The medical records of 124 patients (124 eyes) treated by STTA were reviewed. The age, sex, HbA1c level, best-corrected visual acuity, central macular thickness, insulin use, pioglitazone use, systemic hypertension, serous retinal detachment, proteinuria, panretinal photocoagulation, microaneurysm photocoagulation (MAPC), subthreshold micropulse diode laser photocoagulation (SMDLP), cataract surgery, and history of vitrectomy were examined by logistic regression analysis...
2015: Journal of Ophthalmology
keyword
keyword
61796
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"